tbuckley/cabot-search huggingface dataset:
Acute abdominal pain in childhood.
Authors: B Rodeck
Journal: BMJ (1976)

Acute abdominal pain in children occurs often and requires rapid clarification. Hints as to the condition are often given by the first impression and the case history of the patient. When the clinical examination and laboratory results do not lead to a clear finding, imaging methods such as a sonography can clarify the case. The most common cause for abdominal pain in infants is acute enteritis, mostly brought about by rotaviruses. Additional diagnoses are abdominal hernia, malrotation, hypertrophic pyloric stenosis, invagination or gastroesophageal reflux. In school-age children, the classic finding is "appendicitis". This should be differentiated from constipation, gastritis, pancreatitis, sigmoid volvulus, bowel and intestinal obstruction or, perhaps, gallstone trouble.
Avid Ga-67 uptake in a breast metastasis from cancer of the tongue.
Authors: N Katayama, Y Inoue, M Harada, K Shimoyamada, M Ikeda, Y Tsukune
Journal: Clinical Nuclear Medicine (2001)

KATAYAMA, NOBUHITO M.D.*; INOUE, YUSUKE M.D.†; HARADA, MOTOKO M.D.*; SHIMOYAMADA, KAZUHIRO M.D.*; IKEDA, MITSUNORI M.D.*; TSUKUNE, YOSHIHIKO M.D.* Author Information
SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis
Authors: Tarek M A Abdel-Fatah, Devika Agarwal, Dong-Xu Liu, Roslin Russell, Oscar M Rueda, Karen Liu, Bing Xu, Paul M Moseley, Andrew R Green, Alan G Pockley, Robert C Rees, Carlos Caldas, Ian O Ellis, Graham R Ball, Stephen Y T Chan
Journal: The Lancet Oncology (2016)
SP0078 Clinician Reported Outcome Measures, Croms, in RMDS
Authors: K.G.E. Stigmar
Journal: Annals of the Rheumatic Diseases (2015)

The International Classification of Functioning, Disability and Health (ICF) offers a frame-work for how we better can take into consideration different aspects of life relevant for patients with RMDs. In clinical practice, the main focus is often on medical diagnosis and functional limitations. It is important to also describe activity and participation restrictions and also whether the environment is a facilitator or a barrier. A patient9s status can be described based on laboratory, x-rays and other different types of other measures. Today, patient reported outcome measures (PROMs) and clinician reported outcome measures (CROMs) are widely used. CROMs cover different type of methods such as performance tests, observations and measurements. My presentation will give examples on how ICF can guide us and ensure that we cover different relevant components in assessment and rehabilitation planning. Different CROMs will be presented. Examples from a national rehabilitation program on RMDs, on how CROMs on functions can be used in clinical practice, quality assurance and research, will be given. Furthermore, the session will also invite participants to engage in the discussion on ICF and the usefulness and trustworthiness in CROMs. <h3>Disclosure of Interest</h3> None declared
Case 40-1964
Authors: Bernard M. Jacobson, Benjamin Castleman
Journal: New England Journal of Medicine (1964)

Presentation of Case First admission. A fifty-seven-year-old man was admitted to the hospital because of backache and fatigue.He had been well until three months previously, when he began to experience fatigue, exertional dyspnea and aching in the lumbosacral and substernal regions, without radiation. He became anorectic and lost 15 pounds in weight. During the seven weeks before admission he had urinary frequency, voiding many times each night. There was no history of fever, night sweats, melena, hematuria, undue bruising or bleeding, jaundice, excessive intake of alcohol, orthopnea, paroxysmal nocturnal dyspnea or edema.Physical examination revealed a pale man who . . .
MB-23RECURRENT SHH/TP53 MUTANT MEDULLOBLASTOMA TREATED WITH A COMBINATION OF LITHIUM AND RADIATION THERAPY
Authors: Anne-Sophie Carret, Louis Crevier, Yvan Samson, Benjamin Ellezam, Anne-Marie Charpentier
Journal: Neuro-Oncology (2016)

INTRODUCTION: TP53 mutations remain a poor prognotic factor and account for a high proportion of the treatment failure in SHH subgroup
Replay
Authors: Chunping Wang, Ke‐Qin Hu, Yongping Yang
Journal: Hepatology (2015)

We thank Prof. Hyun for interest in our work. As indicated, radiofrequency ablation (RFA) is considered a curative treatment in patients with cirrhosis and hepatocellular carcinoma (HCC) smaller than 3 cm. With improvements in devices and techniques, many recent studies reported encouraging results, including complete ablation and survival rate of RFA for treating HCC greater than 3 cm.1, 2 Our experiences demonstrated that percutaneous cryotherapy could successfully ablate HCC lesions 5 cm in diameter.3 Based on the above data, we feel it is reasonable to utilize HCC lesions ≤4 cm as the key inclusion criteria for our study for both RFA and cryoablation (CRYO). For patients with tumor diameters of 3.1 to 4.0 cm, the 1-, 3-, and 5-year tumor-free survival (TFS) rates were 86%, 51%, and 29% in the CRYO group and 84%, 49%, and 30% in the RFA group, respectively. There was no significant difference between these two groups (P = 0.88). Consistent with other studies,2 we did not find that tumor size would significantly affect overall survival (OS) and TFS. But there was a significantly lower local tumor progression (LTP) rate in the CRYO group, compared to that in the RFA group (7 of 91 [7.7%] HCC lesions for cryoablation versus 14 of 77 [18.2%] for RFA, P = 0.041). Regarding the effect of the alternative treatment for those with distant tumor recurrence (110 patients) on OS, Prof. Hyun is correct, in that combination therapy using transarterial chemoembolization (TACE), sorafenib, and local ablation could benefit the OS. Considering OS was influenced by many factors, we chose OS and TFS as the secondary endpoints. We did not collect more detailed information, such as the frequency of TACE or local ablation times, duration of sorafenib treatment, and time for conservative management. So, we did not analyze the effect of retreatments of HCC recurrence and metastasis on OS. It should be noted that at the time this study was designed, the greatest concern was the procedure-related complications. Thus, it is important to systemically assess the safety of cryoablation through a randomized, controlled trial (RCT) with comparison to RFA. It is also important to evaluate the efficacy of cryoablation for HCC by a RCT, and the LTP has been a standard measure of the primary endpoints. Our study has demonstrated that percutaneous cryoablation is safe and effective and should be one of the standard ablation modalities for HCC. Chunping Wang, M.Phil.1 Ke-Qin Hu, M.D.2 Yongping Yang, M.D., Ph.D.1 1Center of Therapeutic Research for Hepatocellular Carcinoma the 302nd Hospital Beijing, China 2Division of GI/Hepatology University of California Irvine Irvine, CA
Management of esophageal cancer.
Authors: L Coia, P Engstrom, A Paul, G Hanks
Journal: Journal of Clinical Oncology (1990)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1990.8.7.1285 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2358842 Management of esophageal cancer. L CoiaxL CoiaSearch for articles by this author , P EngstromxP EngstromSearch for articles by this author , A PaulxA PaulSearch for articles by this author , G HanksxG HanksSearch for articles by this author https://doi.org/10.1200/JCO.1990.8.7.1285 PDF "Management of esophageal cancer.." Journal of Clinical Oncology, 8(7), pp. 1285–1286© 1990 by American Society of Clinical Oncology
Comparative biology of decellularized lung matrix: Implications of species mismatch in regenerative medicine
Authors: Jenna L. Balestrini, Ashley L. Gard, Kristin A. Gerhold, Elise C. Wilcox, Angela Liu, Jonas Schwan, Andrew V. Le, Pavlina Baevova, Sashka Dimitrievska, Liping Zhao, Sumati Sundaram, Huanxing Sun, Laure Rittié, Rachel Dyal, Tom J. Broekelmann, Robert P. Mecham, Martin A. Schwartz, Laura E. Niklason, Eric S. White
Journal: Biomaterials (2016)
PNR-02DESMOPLASTIC NON-INFANTILE GANGLIOGLIOMA: A RARE CASE OF MALIGNANT TRANSFORMATION
Authors: Natalie Smith, Bhaskar Thakur, Miren Aizpurua, Angela Calado Bravo, Safa Al-Sarraj, Sanjeev Bassi, Chris Chandler, Bassel Zebian
Journal: Neuro-Oncology (2016)

PNR-02. DESMOPLASTIC NON-INFANTILE GANGLIOGLIOMA: A RARE CASE OF MALIGNANT TRANSFORMATION Natalie Smith, Bhaskar Thakur, Miren Aizpurua, Angela Calado Bravo, Safa Al-Sarraj, Sanjeev Bassi, Chris Chandler, and Bassel Zebian; King’s College Hospital, London, UK INTRODUCTION: Desmoplastic infantile gangliogliomas (DIG) are rare, supratentorial glioneuronal tumours of infants. They are histologically benign and consideredasWHO grade I tumours.When presenting in childrenover the age of 1, they are termed desmoplastic non-infantile ganglioglioma (DNIG). They are not usually associated with malignant behaviour. We present a rare case of recurrent DNIG with malignant transformation. CASE REPORT: A four year-old girl presented with a four-month history of worsening headaches, aggressive behaviour and left facial droop. MRI revealed a large right parieto-occipital lesion with mass effect. The lesion was subtotally resected. Histology was consistent with desmoplastic infantile ganglioglioma, WHO Grade I. Follow up MRIs demonstrated aggressive growth requiring further debulking in 7 months and 10 months. The subsequent biopsies showed similar features; however increasing mitotic activity in the predominant desmin positive astrocytic cells. The proliferation index (Ki67) was focally up to 4% in the first biopsy; increasing to 8% and 12% in the subsequent biopsies. Histology from the third resection was consistent with anaplastic ganglioglioma, WHO Grade III. CONCLUSION: This case of DNIG demonstrated aggressive growth despite multiple operative interventions, and histology strongly suggesting malignant transformation. Histology has shown malignant transformation, which has only been reported in a handful of cases in the literature. This has important implication for the follow up and management of these lesions. Neuro-Oncology 18:iii7–iii15, 2016. doi:10.1093/neuonc/now067.2 #The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Cognitive functioning in depressed geriatric patients with a history of ECT
Authors: H M Pettinati, K M Bonner
Journal: American Journal of Psychiatry (1984)

Cognitive functioning in depressed geriatric patients, some with a history of ECT, was assessed with the Trail Making B test. Depressed patients over the age of 65 who had had at least one prior series of ECT performed more poorly on the test than did older patients with no history of ECT and younger depressed patients regardless of their ECT history. The groups did not differ in severity of depression. Careful assessment of elderly patients' history of ECT will allow for more informed decisions about the current use of ECT and an understanding of the cognitive status of these patients.
RO-18PROTON PENCIL BEAM SCANNING VS VMAT FOR CRANIOSPINAL IRRADIATION IN FULLY GROWN PEDIATRIC PATIENT: A CASE REPORT
Authors: Barbara Rombi, Francesco Fellin, Sabina Vennarini, Nicola Bizzocchi, Paolo Farace, Silvia Cammelli, Giuseppina Paone, Arcangelo Prete, Marco Schwarz, Maurizio Amichetti
Journal: Neuro-Oncology (2016)
Saving Lives One at a Time
Authors: Barry J. Maron
Journal: JAMA Cardiology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Association Between Inferior Vena Cava Filter Insertion in Trauma Patients and In-Hospital and Overall Mortality
Authors: Shayna Sarosiek, Denis Rybin, Janice Weinberg, Peter A. Burke, George Kasotakis, J. Mark Sloan
Journal: JAMA Surgery (2016)

Trauma patients admitted to the hospital are at increased risk of bleeding and thrombosis. The use of inferior vena cava (IVC) filters in this population has been increasing, despite a lack of high-quality evidence to demonstrate their efficacy.To determine if IVC filter insertion in trauma patients affects overall mortality.This retrospective cohort study used stratified 3:1 propensity matching to select a control population similar to patients who underwent IVC filter insertion at Boston Medical Center (a level I trauma center at Boston University School of Medicine) between August 1, 2003, and December 31, 2012. Among patients with an IVC filter and matched controls, age, sex, race/ethnicity, and Injury Severity Score were entered into a multivariable logistic regression model to calculate a propensity score. Matching was stratified by the date of injury.Multivariable logistic regression was used to compare hospital mortality across both groups, adjusting for age, sex, race/ethnicity, Injury Severity Score, and brain injury severity using the head and neck Abbreviated Injury Score. To determine any significant difference in mortality, patient characteristics and mortality data from the National Death Index were analyzed in all patients and in those who survived 24, 48, and 72 hours after injury, as well as at hospital discharge.Among 451 trauma patients with an IVC filter and 1343 matched controls without an IVC filter, the mean (SD) age was 47.4 (21.5) years. The median Injury Severity Score overall was 24 (range, 1-75). Based on a mean follow-up of 3.8 years (range, 0-9.4 years), there was no significant difference in overall mortality or cause of mortality in patients with vs without an IVC filter who survived more than 24 hours from the time of injury, independent of the presence or absence of deep vein thrombosis or pulmonary embolism at the time of IVC filter placement. Additional analyses at shorter intervals of 6 months and 1 year after discharge also showed no significant difference between the 2 groups of patients. Eight percent (38 of 451) of the IVC filters were removed at Boston Medical Center during the follow-up period.The research herein demonstrates no significant difference in survival in trauma patients with vs without placement of an IVC filter, whether in the presence or absence of venous thrombosis. The use of IVC filters in this population should be reexamined because filter removal rates are low and there is increased risk of morbidity in patients with filters that remain in place.
Azidothymidine Inhibition of Thymidine Kinase and Synergistic Cytotoxicity with Methotrexate and 5-Fluorouracil in Rat Hepatoma and Human Colon Cancer Cells
Authors: G Weber, S Ichikawa, M Nagai, Y Natsumeda
Journal: Cancer Communications (1990)

Azidothymidine (AZT, 3'-azido-3'-deoxythymidine, zidovudine) competitively inhibited the activity of thymidine kinase (EC 2.7.1.21) in extracts of rat hepatoma and sarcoma cells; Dixon plots yielded a Ki = 1-2 microM. Azidothymidine (100 microM) exerted synergistic cytotoxicity with methotrexate (0.05 microM) in hepatoma cells in culture in clonogenic assay. Thymidine (50 microM) counteracted the effect of azidothymidine and prevented synergistic action. Azidothymidine (10 microM) was synergistically cytotoxic with 5-fluorouracil (0.3 and 0.5 microM) in HT-29 human colon carcinoma cells. Thymidine (10 microM) abolished synergism. These studies suggest a new role for azidothymidine which, as an inhibitor of thymidine salvage, should enhance synergistically the clinical anticancer impact of blockers of de novo biosynthesis of thymidylates (methotrexate, 5-fluorouracil).
What is "truth"? Some philosophical contributions to psychiatric issues
Authors: E R Wallace
Journal: American Journal of Psychiatry (1988)

Philosophical perspectives, although eminently relevant to clinical investigation and practice, are rarely brought to bear on psychiatric topics. The author attempts to raise professional consciousness of core issues in the philosophy of science by examining the status of truth, theory, and observation in psychiatry. He evaluates prominent approaches to the problem of knowledge, particularly those of the "subjectivists" and "relativists," such as Schafer and Spence, and the "empiricists" and "inductivists," such as the proponents of DSM-III. Drawing on contemporary philosophy of science, the work of William James, and the classical Greek conviction that more truth resides in the middle than at either extreme, the author mediates between these rival points of view.
HG-76SPATIAL AND TEMPORAL HOMOGENEITY OF DRIVER MUTATIONS IN DIFFUSE INTRINSIC PONTINE GLIOMA
Authors: Eshini Panditharatna, Hamid Nikbakht, Leonie Mikael, Rui Li, Tenzin Gayden, Matthew Osmand, Cheng-Ying Ho, Madhuri Kambhampati, Eugene I. Hwang, Damien Faury, Alan Siu, Simon Papillon-Cavanagh, Denise Bechet, Keith L. Ligon, Benjamin Ellezam, Wendy J. Ingram, Caedyn Stinson, Andrew S. Moore, Katherine E. Warren, Jason Karamchandani, Roger J. Packer, Nada Jabado, Jacek Majewski, Javad Nazarian
Journal: Neuro-Oncology (2016)
Aortic Valve Replacement and the Ross Operation in Children and Young Adults
Authors: Mansour T.A. Sharabiani, Dan M. Dorobantu, Alireza S. Mahani, Mark Turner, Andrew J. Peter Tometzki, Gianni D. Angelini, Andrew J. Parry, Massimo Caputo, Serban C. Stoica
Journal: Journal of the American College of Cardiology (2016)
Iodine-125 in hyperthyroidism.
Authors: J BARZELATTO
Journal: BMJ (1972)

Birmingham, reviewed 25 patients who had undergone this operation.In eight cases there were postoperative leakages of the anastomosis, with one death, and these occurred even in the presence of a safety-valve ileostomy.Two other patients in the series died and 10 required further resection, four having a new anastomosis performed and the rest having an ileostomy.Of the whole group, 10 (40%) ultimately had a successful ileorectal anastomosis, two of these after a second resection of the recurrence.Since re- currence may also follow proctocolectomy, these authors consider that the ileorectal anastomosis remains a suitable procedure for Crohn's disease of the large bowel.F. T. de Dombal and his colleagues'3 from Leeds found that recurrence after surgery is particularly likely in children affected with Crohn's disease, and the per- centage of recurrence drops with increasing age.B. I. Korelitz'4 has also pointed out the gloomy prognosis when the disease affects the large bowel with onset in childhood.Recurrence is more likely to follow resections of small intestine (40-4%) than of large intestine (11-8%), but in- terestingly enough when both the large and small intestine were involved the recurrence rate was the same as in cases affecting the small intestine only.The recurrence was usually in the small intestine proximal to the anastomosis and was usually either in the period one to two years after operation or in the period five to fifteen years after it; the outlook was graver in the former group.Of the patients with re- currences, one-third were managed conservatively, and those undergoing a second operation were found not to have a higher risk of requiring further surgery than patients under- going a primary operation.At review some 70% of the patients with a recurrence were in good or very good health, and about three-quarters were satisfied with the outcome of treatment.
Vasodilator Drugs in Peripheral Vascular Disease
Authors: Jan Koch-Weser, Jay D. Coffman
Journal: New England Journal of Medicine (1979)

DRUGS that increase blood flow by direct or indirect action on the peripheral blood vessels are termed "vasodilators." These agents are widely advertised in medical journals and consume a substantial percentage of the drug dollar in this country.1 Although most vasodilator drugs have been shown to increase blood flow to the limbs and various organs in animal experiments and sometimes in normal human subjects, their use in peripheral vascular diseases remains questionable.For therapeutic purposes, peripheral vascular diseases can be generally classified into obstructive or vasospastic; the most common examples of each category are arteriosclerosis obliterans and Raynaud's disease, respectively. . . .
Studies in Species Adaptation. III. Continuous Exposure of Paramecia to Methylcholanthrene and Other Agents for More than Five Years&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/xref&gt;
Authors: R. R. Spencer, Dorothy Calnan
Journal: JNCI Journal of the National Cancer Institute (1945)

Journal Article Studies in Species Adaptation. III. Continuous Exposure of Paramecia to Methylcholanthrene and Other Agents for More than Five Years Get access R. R. Spencer, R. R. Spencer Chief National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Dorothy Calnan Dorothy Calnan junior bacteriologist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 6, Issue 3, December 1945, Pages 147–154, https://doi.org/10.1093/jnci/6.3.147 Published: 01 December 1945
Effect of Absolute Caloric Deprivation on Thyroid Hormone Synthesis and Release in the Rat
Authors: R M DONATI, M A WARNECKE, N I GALLAGHER
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
EPT-10PHASE I CLINICAL TRIAL OF HSV G207 ALONE OR WITH A SINGLE RADIATION DOSE IN CHILDREN WITH RECURRENT SUPRATENTORIAL BRAIN TUMORS (NCT02457845)
Authors: Alyssa Reddy, James Johnston, Avi Madan-Swain, John Fiveash, Asim Bag, G. Yancey Gillespie, James Markert, Gregory Friedman
Journal: Neuro-Oncology (2016)